Nephrology
Conference Coverage
Combo B-cell depletion advances in SLE
SAN FRANCISCO – Double-punch with rituximab/belimumab is now in phase 3 for SLE.
Conference Coverage
Low-dose IL-2 found effective in SLE
SAN FRANCISCO – Lupus nephritis remission occurred in more than half of affected patients.
Conference Coverage
Dr. Joseph Vassalotti: Cancer risk minimal with ARBs
PHILADELPHIA - "I've been telling everyone not to stop on their own," said the senior officer of the National Kidney Foundation.
From the Journals
Canagliflozin lowers kidney failure risk in T2D: CREDENCE
The SGLT2 inhibitor also cut cardiovascular events.
News
New renal, CV disease indication sought for canagliflozin
Canagliflozin is currently indicated for patients with type 2 diabetes but may soon help treat those who also have chronic kidney disease.
From the Journals
Newer antihyperglycemic drugs have distinctive CV, kidney benefits
SGLT2 inhibitors and GLP-1 RAs have different effects on cardiovascular and kidney disease outcomes in patients with type 2 diabetes.
Pearl of the Month
A couple of little known side effects of medications
The cause of one patient’s acidosis and the correct blood pressure medication for another patient.
News
FDA approves label extension for dapagliflozin
The label extension means a broader population with type 2 diabetes and impaired renal function could benefit from treatment with dapagliflozin....
From the Journals
Renal transplant improves survival in lupus nephritis patients
Transplant conferred a 70% reduction in overall death risk in patients with end-stage renal disease due to lupus nephritis.
Conference Coverage
Difelikefalin shows promise for hemodialysis-associated itch
PARIS – There is no approved medication in the United States or Europe for the often intense itching associated with chronic kidney disease.
Conference Coverage
New diabetes drugs solidify their cardiovascular and renal benefits
CHICAGO –